----
Current ValuationThe current P/E ratio is -23.44, below the reasonable range, cheaper than 87.6% of the time in the past 3 years, and the industry ranks 46/58, the industry Median -2.13.
-23.44xP/E
$21.00Stock price
$-0.90Earnings per share
-23.44xP/E
Stock price$21.00Earnings per share$-0.90
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -3.46x
- Typical range
- -20.05x–-0.86x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
010203040
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
LZAGYUSLonza | -348.77x | -- | $48.02B |
CRLUSCharles River Laboratorie | -60.43x | 242.15% | $14.41B |
TEMUSTempus AI | -47.94x | 1.10% | $12.20B |
AVTRUSAvantor | -18.13x | 144.24% | $10.48B |
TXGUS10X Genomics | -130.40x | 107.10% | $9.80B |
BRKRUSBruker | -80.17x | 7.71% | $8.57B |
ABCLUSAbcellera Biologics | -24.87x | 36.29% | $4.09B |
ADPTUSAdaptive Biotechnologies | -63.91x | 39.25% | $4.08B |
FTREUSFortrea | -23.44x | 93.77% | $2.00B |
MRVIUSMaravai LifeSciences | -23.69x | 64.44% | $1.83B |
PSNLUSPersonalis | -15.74x | 18.68% | $1.69B |
ALMRUSAlamar Biosciences | -33.87x | 80.55% | $1.68B |
AZTAUSAzenta | -13.46x | 180.77% | $1.65B |
CYRXUSCryoport | -18.79x | 156.25% | $852.93M |
DNAUSGinkgo Bioworks | -2.73x | 35.20% | $793.94M |
OABIUSOmniAb | -15.67x | 35.96% | $693.51M |
CTKBUSCytek Biosciences | -8.57x | 33.98% | $690.21M |
PACBUSPacific Biosc California | -4.97x | 75.69% | $652.74M |
EVOUSEvotec SE | -2.13x | 375.71% | $486.64M |
TKNOUSAlpha Teknova | -27.85x | 5.80% | $467.09M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
